RxDoctor Payments Data

Ann Murray, MD

Neurology · Morgantown, WVNPI 1194081968

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Insightec,inc accounts for 71.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $5,708 and has fallen 65.9% since, to $1,946 in 2025.

$12,410in general payments, 2019–2025

Across 69 payments — averaging $179.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insightec,inc$9K
  • Medtronic$3K
  • Abbott$108
  • MDD US Operations, LLC$49
  • AbbVie$27
  • Boston Scientific$23
  • plus $51 from 3 others
$253,627in research payments, 2019–2025

Across 54 payments — averaging $4696.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$254K

What the payments were for

  • Consulting fees$5,74846%
  • Travel & lodging$4,79639%
  • Food & beverage$1,86615%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,410 in reported general payments places this provider in the 80th percentile of 93 neurology providers in West Virginia.

See all neurology providers in West Virginia

Medicare billing

Part B allowed, 2024
$58,719
Medicare patients
185
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone11$352,237
RytaryCarbidopa/Levodopa12$12,823
Carbidopa-LevodopaCarbidopa/Levodopa188$8,450
Dalfampridine ErDalfampridine17$8,322
Carbidopa-Levodopa ErCarbidopa/Levodopa115$6,772
Propranolol Hcl32$1,313
AmantadineAmantadine Hcl16$1,273
Gabapentin25$1,167
Primidone23$878
Donepezil Hcl28$376
Topiramate17$317
Escitalopram Oxalate13$289
Sertraline Hcl12$276
Phenobarbital12$262
Lamotrigine13$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$16$352,23711 claims
Amneal Pharmaceuticals LLCRytary$14$12,82312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 neurology providers in West Virginia.

Other neurology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →